Atlas Trials

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Clinical trial NCT04905212 · TERMINATED

Trial details

NCT number
NCT04905212
Sponsor
RemeGen Co., Ltd.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
IgA Nephropathy
Start date
2021-11-04
Primary completion
2023-11-09
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.